Home › Esophageal Cancer › Arizona › Tucson
Esophageal Cancer clinical trials in Tucson, AZ
3 studies for Esophageal Cancer are looking for participants at sites in and around Tucson (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
RecruitingPhase 1/2
- University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927), Tucson
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RecruitingPhase 1/2
- University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 8927), Tucson
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
RecruitingPhase 1/2
- University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927), Tucson
About Esophageal Cancer
Early esophageal cancer does not have symptoms. Factors that increase risk include heavy drinking and smoking. Learn how you can reduce your risk.
More about Esophageal Cancer on MedlinePlus
Esophageal Cancer trials in other cities
- Houston, TX36 studies
- Boston, MA23 studies
- New York City, NY22 studies
- Nashville, TN19 studies
- St. Louis, MO17 studies
- Pittsburgh, PA15 studies
- Los Angeles, CA15 studies
- Baldwin Park, CA14 studies
- Grand Rapids, MI14 studies
- Philadelphia, PA13 studies
- San Antonio, TX12 studies
- Chicago, IL11 studies
Other studies in Tucson
- Breast Cancer20 studies
- Obesity18 studies
- Non-Small Cell Lung Cancer17 studies
- Overweight15 studies
- Metastatic Cancer14 studies
- Cancer (all types)12 studies
- Cardiovascular Disease12 studies
- Colorectal Cancer11 studies
- Prostate Cancer11 studies
- Type 2 Diabetes11 studies
- Steatotic Liver Disease10 studies
- Heart Failure10 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.